



[ADC Therapeutics announces first patient dosed in Phase I clinical trial of ADCT-601 in advanced solid tumors](#)

01/18/2019/[0 Comments](#)/in [News](#) /by [CAPTIS](#)

ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of proprietary antibody drug conjugates (ADCs), today announced that the first patient has been The post ADC Therapeutics announces first patient dosed in Phase I clinical trial of ADCT-601 in advanced solid tumors appeared first on Pharmaceutical Business review.

[Read more](#)

<https://www.captis.com/wp-content/uploads/2017/02/004.jpg> 450 900 CAPTIS

https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png

CAPTIS2019-01-18 00:01:452019-01-18 01:01:47ADC Therapeutics announces first patient dosed in Phase I clinical trial of ADCT-601 in advanced solid tumors



[Acrotech to buy seven hematology/oncology products from Spectrum](#)

01/17/2019/[0 Comments](#)/in [News](#) /by [CAPTIS](#)

Under the deal, Spectrum will secure \$160m in an upfront cash payment, while up to \$140m in regulatory and sales-based milestones. Spectrum Pharmaceuticals president and CEO Joe Turgeon The post Acrotech to buy seven hematology/oncology products from Spectrum appeared first on Pharmaceutical Business review.

[Read more](#)

<https://www.captis.com/wp-content/uploads/2017/02/004.jpg> 450 900 CAPTIS
https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png
CAPTIS2019-01-17 23:31:192019-01-18 00:31:20Acrotech to buy seven
hematology/oncology products from Spectrum



[Schott to invest €300m in pharmaceutical packaging buisness](#)

01/17/2019/[0 Comments](#)/in [News](#) /by [CAPTIS](#)

Through the investment, Schott plans to expand its primary business of glass tubing, used as the starting material for pharmaceutical packaging, and also pharmaceutical packaging made of glass and The post Schott to invest €300m in pharmaceutical packaging buisness appeared first on Pharmaceutical Business review.

[Read more](#)

<https://www.captis.com/wp-content/uploads/2017/02/004.jpg> 450 900 CAPTIS
https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png

CAPTIS2019-01-17 23:31:172019-01-18 00:31:18Schott to invest €300m in pharmaceutical packaging business



[Abbott inks deal to test blood donations in Japan](#)

01/17/2019/0 Comments/in [Abbott](#), [Blog](#), [Blood Management](#), [Business/Financial News](#), [japaneseredcrosssociety](#), [News Well](#) /by [CAPTIS](#)

Abbott (NYSE:ABT) said today that it has been selected by the Japanese Red Cross Society (JRC) to partner in screening the country's blood donations. The eight-year contract is for the exclusive supply of serological instrumentation, tests, and consumables used for blood and plasma screening. The JRC screens approximately 5 million blood donations each year, helping ensure a [...]

[Read more](#)

<https://www.captis.com/wp-content/uploads/2019/01/Abbottlogolarge-300x195.jpg> 195 300
CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png
CAPTIS2019-01-17 11:06:572019-01-17 12:31:29Abbott inks deal to test blood donations in Japan



[Windgap Medical raises \\$12m for epinephrine auto-injector](#)

01/17/2019/0 Comments/in [Drug-Device Combinations](#), [Featured](#), [Funding Roundup](#),

[Pharmaceuticals](#), [Respiratory](#), [Windgap Medical](#) /by [CAPTIS](#)

Windgap Medical has raised \$12 million from 106 investors as part of a \$27 million round, according to a document filed with the SEC. The Watertown, Mass.-based company is developing an epinephrine auto-injector designed to treat severe allergic reactions. Get the full story at our sister site, Drug Delivery Business News. The post Windgap Medical raises \$12m for [...]

[Read more](#)

<https://www.captis.com/wp-content/uploads/2019/01/windgap-medical-updated-150x97.jpg>
97 150 CAPTIS

https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png
CAPTIS2019-01-17 09:42:122019-01-17 11:01:36Windgap Medical raises \$12m for epinephrine auto-injector



[**HighLife raises \\$36m Series B for mitral valve replacement**](#)

01/17/2019/0 [Comments](#)/in [Featured](#), [Funding Roundup](#), [HighLife](#), [Replacement Heart Valves](#), [Wall Street Beat](#) /by [CAPTIS](#)

HighLife said today that it raised a Series B round worth more than \$36 million for the transcatheter mitral valve replacement it's developing. HighLife's TMVR uses a ring around the diseased valve's leaflets that's designed to guide the replacement valve into position. It's designed to be delivered through the inter-atrial septum, rather than via a trans-apical [...]

[Read more](#)

<https://www.captis.com/wp-content/uploads/2019/01/highlife-150x97.jpg> 97 150 CAPTIS
https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png
CAPTIS2019-01-17 09:31:212019-01-17 11:01:33HighLife raises \$36m Series B for mitral valve replacement



[LivaNova touts studies of its sutureless aortic valve](#)

01/17/2019/[0 Comments](#)/in [Blog](#) /by [CAPTIS](#)

LivaNova (NSDQ:LIVN) said today that three separate, recently published studies highlight the performance and cost savings of its sutureless aortic valve, Perceval. The results from the Perceval Aortic Heart Valve Study in North America found that Perceval achieves positive safety and efficacy outcomes whether or not an open or minimally invasive surgical approach is used. The [...]

[Read more](#)

<https://www.captis.com/wp-content/uploads/2019/01/LivaNovalogolarge-300x195.jpg> 195
300 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png
CAPTIS2019-01-17 08:31:312019-01-17 10:01:13LivaNova touts studies of its sutureless
aortic valve



[OtoNexus raises \\$4.4 million for ear infection detection](#)

technology

01/17/2019/0 Comments/in [Business/Financial News](#), [Diagnostics](#), [Featured](#), [Funding Roundup](#), [OtoNexus Medical Technologies](#), [Ultrasound](#) /by [CAPTIS](#)

OtoNexus (Seattle) has raised more than \$4.4 million as it continues to develop its ultrasound medical device technology to diagnose middle ear infections, according to a U.S. Securities and Exchange Commission Form D filed this month. OtoNexus has been seeking a nearly \$8.3 million from the money-raise. It previously raised \$7.8 million in 2017. Get the full [...]

[Read more](#)

<https://www.captis.com/wp-content/uploads/2019/01/otonexus-medical-technologies-7x4-300x171.png> 171 300 CAPTIS

https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png

CAPTIS2019-01-17 08:08:192019-01-17 09:31:13OtoNexus raises \$4.4 million for ear infection detection technology



Johnson & Johnson, Apple ink collab for AFib study

01/17/2019/0 Comments/in [Apple](#), [Business/Financial News](#), [Cardiovascular](#), [Drug-Device Combinations](#), [Featured](#), [Janssen Pharmaceuticals](#), [johnsonandjohnson](#), [mHealth \(Mobile Health\)](#), [Pharmaceuticals](#), [Vascular](#), [Wall Street Beat](#) /by [CAPTIS](#)

Johnson & Johnson's (NYSE:JNJ) Janssen and Apple (NSDQ:AAPL) said today that the two companies inked a deal to study if an app from J&J in combination with the Apple Watch's ECG app and irregular rhythm notifications can improve outcomes for people living with atrial fibrillation. The study is slated to measure the impact of the Apple Watch on the [...]

[Read more](#)

<https://www.captis.com/wp-content/uploads/2019/01/janssen-logo-updated-150x97.png> 97 150 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2019-01-17 07:40:552019-01-17 09:01:27Johnson & Johnson, Apple ink collab for AFib study



Critical impacts of the government shutdown on the FDA and clinical research

01/17/2019/[0 Comments](#)/in [Blog](#), [IMARC](#) /by [CAPTIS](#)

Rachel Martukovich, Clinical Research Associate for IMARC Research, Inc. The recent partial government shutdown, which is now the longest in US history, has various stakeholders in the medical device and pharmaceutical industries concerned with the potential impact on the world of clinical research. The FDA is one of the federal agencies most affected, as the [...]

[Read more](#)

<https://www.captis.com/wp-content/uploads/2019/01/IMARC-logo-new-300x195.png> 195 300
CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png
CAPTIS2019-01-17 07:37:062019-01-17 09:01:24Critical impacts of the government
shutdown on the FDA and clinical research
Page 1 of 487123>>